<DOC>
	<DOCNO>NCT00004231</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Biological therapy use different way stimulate immune system stop cancer cell grow . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow bone marrow peripheral stem cell transplantation and/or biological therapy treat patient stage III , stage IV , recurrent mantle cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Bone Marrow Peripheral Stem Cell Transplantation , and/or Biological Therapy Treating Patients With Stage III Stage IV Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity combination chemotherapy follow allogeneic autologous bone marrow transplantation peripheral blood stem cell transplantation and/or interferon interleukin therapy patient refractory stage III IV mantle cell lymphoma . - Determine complete response rate patient treatment . - Evaluate prognostic factor patient population . OUTLINE : This multicenter study . Patients receive induction chemotherapy consist cyclophosphamide IV , doxorubicin IV , teniposide IV 2 hour day 1 , oral prednisone day 1-5 , vincristine IV methotrexate IV 2 hour day 21 , cytarabine IV 2 hour every 12 hour total 2 dos day 22 , oral leucovorin calcium every 6 hour begin day 22 continue methotrexate level recover . Treatment repeat every 42 day 2 course . Patients achieve complete response partial response receive additional course induction therapy . Patients achieve maximal response follow 2 course induction chemotherapy undergo transplantation . Patients 50 year HLA match donor undergo allogeneic bone marrow transplantation ( BMT ) . Patients receive busulfan IV every 6 hour total 14 dos begin day -8 continue 3.5 day . At 24 hour follow last dose busulfan , patient receive cyclophosphamide IV 2 hour daily 2 day . Patients receive allogeneic bone marrow infusion day 0 . Patients 50 year HLA match donor patient 50-65 year old undergo autologous bone marrow peripheral blood stem cell ( PBSC ) transplantation . Patients undergo PBSC mobilization follow completion cyclophosphamide , doxorubicin , teniposide portion induction therapy course 3 . Patients receive cytokine subcutaneously ( SQ ) begin 2 day follow chemotherapy continue PBSC collection . If insufficient stem cell collect negative bone marrow involvement , patient undergo bone marrow harvest . Patients receive condition regimen consist busulfan cyclophosphamide allogeneic BMT . Patients receive autologous bone marrow PBSC infusion day 0 filgrastim ( G-CSF ) SQ begin day 0 continue blood count recover . Following blood count recovery , patient receive maintenance therapy consist interferon alfa SQ interleukin-2 SQ daily 5 consecutive day 4 week . Treatment repeat every 8 week 2 course . Patients 65 year old achieve complete partial response induction chemotherapy receive maintenance therapy autologous BMT . Patients achieve partial response may receive additional 4th course induction therapy prior maintenance therapy . Patients follow 30 day post transplant , every 3 month 1 year , least every 6 month 2 year . PROJECTED ACCRUAL : A total 15-48 patient accrue study 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III , IV , recurrent mantle cell lymphoma CD5 positive OR Evidence bcl1 oncogene overexpression Measurable evaluable disease least one following : Clear cut radiographic finding Clearly define bidimensional defect mass least 2 cm diameter radionuclide CT scan Enlarged spleen extend least 2 cm costal margin lymphomatous involvement Enlarged liver proof lymphoma biopsy CNS involvement allow Fully HLA match donor allogeneic transplantation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3.0 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No significant cardiac disease Other : No prior malignancy except previously treat nonmelanoma skin cancer carcinoma situ cervix No medical problem would preclude study HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Prior chemotherapy , include doxorubicin , allow Endocrine therapy : See Disease Characteristics Prior steroid allow Radiotherapy : See Disease Characteristics Prior radiotherapy allow exclude indicator lesion Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>